Prader-Willi Syndrome (PWS) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2000

Prader-Willi Syndrome (PWS) is a rare genetic disorder present at birth that results in several physical, mental, and behavioral problems. PWS is due to the lack of several genes on one of an individual’s two chromosome 15s. In most cases, there is a deletion. In remaining cases, the entire chromosome from the father is missing and there are instead two chromosome 15s from the mother (uniparental disomy). Symptoms include poor muscle tone, low levels of sex hormones, and a constant feeling of hunger.

The Prader-Willi Syndrome drugs in development market research report provide comprehensive information on the therapeutics under development for Prader-Willi Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Prader-Willi Syndrome and features dormant and discontinued projects.

Key Targets in the Prader-Willi Syndrome Pipeline Products Market

The key targets in the Prader-Willi Syndrome pipeline products market are Oxytocin Receptor, Cannabinoid Receptor 1, Cannabinoid Receptor 2, Gastric Inhibitory Polypeptide, Growth Hormone Secretagogue Receptor Type 1, Histamine H3 Receptor, Sodium Dependent Dopamine Transporter, Sodium Dependent Noradrenaline Transporter, Sodium Dependent Serotonin Transporter, 5-Hydroxytryptamine Receptor 2A, and others.

Prader-Willi Syndrome Pipeline Products Analysis Market by Targets

Prader-Willi Syndrome Pipeline Products Analysis Market by Targets

For more target insights, download a free report sample

Key Mechanisms of Action in the Prader-Willi Syndrome Pipeline Products Market

The key mechanisms of action in the Prader-Willi Syndrome pipeline products market are Oxytocin Receptor Agonist, Cannabinoid Receptor 1 Agonist, Cannabinoid Receptor 1 Antagonist, Cannabinoid Receptor 2 Agonist, Histamine H3 Receptor Antagonist, Sodium Dependent Dopamine Transporter Inhibitor, Sodium Dependent Noradrenaline Transporter Inhibitor, Sodium Dependent Serotonin Transporter Inhibitor, 5-Hydroxytryptamine Receptor 2A Agonist, 5-Hydroxytryptamine Receptor 2C Agonist, and others.

Prader-Willi Syndrome Pipeline Products Market Analysis by Mechanism of Actions

Prader-Willi Syndrome Pipeline Products Market Analysis by Mechanism of Actions

For more mechanism of actions insights, download a free report sample

Key Routes of Administration in the Prader-Willi Syndrome Pipeline Products Market

The key routes of administration in the Prader-Willi Syndrome pipeline products market are oral, nasal, intramuscular, intrathecal, parenteral, and topical.

Prader-Willi Syndrome Pipeline Products Market Analysis by Routes of Administration

Prader-Willi Syndrome Pipeline Products Market Analysis by Routes of Administration

For more routes of administration insights, download a free report sample

Key Molecule Types in the Prader-Willi Syndrome Pipeline Products Market

The key molecule types in the Prader-Willi Syndrome pipeline products market are small molecule, synthetic peptide, biologic, monoclonal antibody, and RNAi gene therapy.

Prader-Willi Syndrome Pipeline Products Market Analysis by Molecule Type

Prader-Willi Syndrome Pipeline Products Market Analysis by Molecule Type

For more molecule type insights, download a free report sample

Major Companies in the Prader-Willi Syndrome Pipeline Products Market

Some of the major companies in the Prader-Willi Syndrome pipeline products market are Benuvia Therapeutics Inc, 9 Meters Biopharma Inc, Aardvark Therapeutics Inc, Altamira Therapeutics Ltd, Beryl Therapeutics Inc, Biomind Labs Inc, Bioprojet SCR, Carmot Therapeutics Inc, ConSynance Therapeutics Inc, and Ferring International Center SA.

Prader-Willi Syndrome Pipeline Products Market Analysis by Companies

Prader-Willi Syndrome Pipeline Products Market Analysis by Companies

To know more about major companies, download a free report sample

Market Report Overview

Key targets Oxytocin Receptor, Cannabinoid Receptor 1, Cannabinoid Receptor 2, Gastric Inhibitory Polypeptide, Growth Hormone Secretagogue Receptor Type 1, Histamine H3 Receptor, Sodium Dependent Dopamine Transporter, Sodium Dependent Noradrenaline Transporter, Sodium Dependent Serotonin Transporter, 5-Hydroxytryptamine Receptor 2A, and Others
Key mechanism of action Oxytocin Receptor Agonist, Cannabinoid Receptor 1 Agonist, Cannabinoid Receptor 1 Antagonist, Cannabinoid Receptor 2 Agonist, Histamine H3 Receptor Antagonist, Sodium Dependent Dopamine Transporter Inhibitor, Sodium Dependent Noradrenaline Transporter Inhibitor, Sodium Dependent Serotonin Transporter Inhibitor, 5-Hydroxytryptamine Receptor 2A Agonist, 5-Hydroxytryptamine Receptor 2C Agonist, and Others
Key routes of administration Oral, Nasal, Intramuscular, Intrathecal, Parenteral, and Topical
Key molecule type Small Molecule, Synthetic Peptide, Biologic, Monoclonal Antibody, and RNAi Gene Therapy
Major companies Benuvia Therapeutics Inc, 9 Meters Biopharma Inc, Aardvark Therapeutics Inc, Altamira Therapeutics Ltd, Beryl Therapeutics Inc, Biomind Labs Inc, Bioprojet SCR, Carmot Therapeutics Inc, ConSynance Therapeutics Inc, and Ferring International Center SA

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Prader-Willi Syndrome (PWS) (Genetic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Prader-Willi Syndrome (PWS) (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Prader-Willi Syndrome (PWS) (Genetic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Prader-Willi Syndrome (PWS) (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for Prader-Willi Syndrome (PWS) (Genetic Disorders)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Prader-Willi Syndrome (PWS) (Genetic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Prader-Willi Syndrome (PWS) (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

9 Meters Biopharma Inc
Aardvark Therapeutics Inc
Altamira Therapeutics Ltd
Benuvia Therapeutics Inc
Beryl Therapeutics Inc
Biomind Labs Inc
Bioprojet SCR
Carmot Therapeutics Inc
ConSynance Therapeutics Inc
Ferring International Center SA
GLWL Research Inc
Helsinn Group
Inversago Pharma Inc
Lipidio Pharmaceuticals Inc
Lumos Pharma Inc
Neuracle Science Co Ltd
Neuren Pharmaceuticals Ltd
Notitia Biotechnologies Co
OptiNose Inc
OT4B
Saniona AB
Soleno Therapeutics Inc
Taysha Gene Therapies Inc
Tonix Pharmaceuticals Holding Corp

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Prader-Willi Syndrome (PWS) – Overview

Prader-Willi Syndrome (PWS) – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Prader-Willi Syndrome (PWS) – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Prader-Willi Syndrome (PWS) – Companies Involved in Therapeutics Development

9 Meters Biopharma Inc

Aardvark Therapeutics Inc

Altamira Therapeutics Ltd

Benuvia Therapeutics Inc

Beryl Therapeutics Inc

Biomind Labs Inc

Bioprojet SCR

Carmot Therapeutics Inc

ConSynance Therapeutics Inc

Ferring International Center SA

GLWL Research Inc

Helsinn Group

Inversago Pharma Inc

Lipidio Pharmaceuticals Inc

Lumos Pharma Inc

Neuracle Science Co Ltd

Neuren Pharmaceuticals Ltd

Notitia Biotechnologies Co

OptiNose Inc

OT4B

Saniona AB

Soleno Therapeutics Inc

Taysha Gene Therapies Inc

Tonix Pharmaceuticals Holding Corp

Prader-Willi Syndrome (PWS) – Drug Profiles

(metoprolol + tesofensine) – Drug Profile

Product Description

Mechanism Of Action

History of Events

betahistine dihydrochloride – Drug Profile

Product Description

Mechanism Of Action

History of Events

Biologic for Prader Willi Syndrome – Drug Profile

Product Description

Mechanism Of Action

Bittera – Drug Profile

Product Description

Mechanism Of Action

BMND-04 – Drug Profile

Product Description

Mechanism Of Action

cannabidiol – Drug Profile

Product Description

Mechanism Of Action

History of Events

carbetocin LA – Drug Profile

Product Description

Mechanism Of Action

History of Events

CSTI-500 – Drug Profile

Product Description

Mechanism Of Action

diazoxide choline CR – Drug Profile

Product Description

Mechanism Of Action

History of Events

GDD-3898 – Drug Profile

Product Description

Mechanism Of Action

GLWL-01 – Drug Profile

Product Description

Mechanism Of Action

History of Events

HM-04 – Drug Profile

Product Description

Mechanism Of Action

History of Events

HU-671 – Drug Profile

Product Description

Mechanism Of Action

ibutamoren mesylate – Drug Profile

Product Description

Mechanism Of Action

History of Events

INV-202 – Drug Profile

Product Description

Mechanism Of Action

History of Events

MRI-1867 – Drug Profile

Product Description

Mechanism Of Action

History of Events

NM-136 – Drug Profile

Product Description

Mechanism Of Action

History of Events

NNZ-2591 – Drug Profile

Product Description

Mechanism Of Action

History of Events

NS-200 – Drug Profile

Product Description

Mechanism Of Action

oxytocin – Drug Profile

Product Description

Mechanism Of Action

oxytocin – Drug Profile

Product Description

Mechanism Of Action

History of Events

oxytocin – Drug Profile

Product Description

Mechanism Of Action

History of Events

oxytocin – Drug Profile

Product Description

Mechanism Of Action

History of Events

pitolisant hydrochloride – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule to Activate snRNP-N for Prader-Willi Syndrome – Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Inhibit SMCHD1 for Prader Willi Syndrome – Drug Profile

Product Description

Mechanism Of Action

Synthetic Peptides to Target Incretin for Prader-Willi syndrome – Drug Profile

Product Description

Mechanism Of Action

History of Events

TSHA-116 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Prader-Willi Syndrome (PWS) – Dormant Projects

Prader-Willi Syndrome (PWS) – Discontinued Products

Prader-Willi Syndrome (PWS) – Product Development Milestones

Featured News & Press Releases

Mar 09, 2022: Running for research – Prader-Willi Syndrome to fund multi-center study of DCCR in early phase Prader-Willi syndrome

Mar 03, 2022: Tonix Pharmaceuticals announces FDA Orphan-Drug Designation for TNX-2900 for the treatment of Prader-Willi Syndrome

Feb 28, 2022: Tonix Pharmaceuticals announces research agreement with the French National Institute of Health and Medical Research (Inserm) to study the mechanism of oxytocin-mediated improvement of eating behaviors in Prader-Willi Mice

Feb 03, 2022: Aardvark starts enrolment in three Phase II trials of TAS2R agonist

Jan 24, 2022: Soleno Therapeutics provides regulatory update on DCCR for the treatment of Prader-Willi syndrome

Dec 28, 2021: Saniona initiates phase 2b clinical trial of tesomet for Prader-Willi syndrome

Oct 18, 2021: Saniona completes submission of manufacturing data for Tesomet capsules to U.S. FDA

Oct 11, 2021: US patent to 2034 granted for Neuren’s NNZ-2591 in autism

Sep 17, 2021: adMare Portfolio Company, Inversago Pharma initiates a phase 1 clinical trial on INV-202, a next generation peripherally-acting CB1 Blocker

Sep 08, 2021: Soleno Therapeutics announces positive data showing continued significant improvements in symptoms of PWS following one year treatment with DCCR

Sep 07, 2021: Inversago Pharma initiates a phase 1 clinical trial on INV-202, a next generation peripherally-acting CB1 blocker

Sep 03, 2021: FDA grants Orphan Drug Designation for NNZ-2591 to treat Prader-Willi syndrome

Jul 26, 2021: Saniona receives U.S. FDA orphan drug designation for Tesomet in hypothalamic obesity

Jul 22, 2021: Radius Health announces plans for global Prader-Willi syndrome pivotal study

Jul 06, 2021: Soleno Therapeutics provides regulatory update on DCCR for the treatment of Prader-Willi syndrome

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Prader-Willi Syndrome (PWS), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Prader-Willi Syndrome (PWS) – Pipeline by 9 Meters Biopharma Inc, 2022

Prader-Willi Syndrome (PWS) – Pipeline by Aardvark Therapeutics Inc, 2022

Prader-Willi Syndrome (PWS) – Pipeline by Altamira Therapeutics Ltd, 2022

Prader-Willi Syndrome (PWS) – Pipeline by Benuvia Therapeutics Inc, 2022

Prader-Willi Syndrome (PWS) – Pipeline by Beryl Therapeutics Inc, 2022

Prader-Willi Syndrome (PWS) – Pipeline by Biomind Labs Inc, 2022

Prader-Willi Syndrome (PWS) – Pipeline by Bioprojet SCR, 2022

Prader-Willi Syndrome (PWS) – Pipeline by Carmot Therapeutics Inc, 2022

Prader-Willi Syndrome (PWS) – Pipeline by ConSynance Therapeutics Inc, 2022

Prader-Willi Syndrome (PWS) – Pipeline by Ferring International Center SA, 2022

Prader-Willi Syndrome (PWS) – Pipeline by GLWL Research Inc, 2022

Prader-Willi Syndrome (PWS) – Pipeline by Helsinn Group, 2022

Prader-Willi Syndrome (PWS) – Pipeline by Inversago Pharma Inc, 2022

Prader-Willi Syndrome (PWS) – Pipeline by Lipidio Pharmaceuticals Inc, 2022

Prader-Willi Syndrome (PWS) – Pipeline by Lumos Pharma Inc, 2022

Prader-Willi Syndrome (PWS) – Pipeline by Neuracle Science Co Ltd, 2022

Prader-Willi Syndrome (PWS) – Pipeline by Neuren Pharmaceuticals Ltd, 2022

Prader-Willi Syndrome (PWS) – Pipeline by Notitia Biotechnologies Co, 2022

Prader-Willi Syndrome (PWS) – Pipeline by OptiNose Inc, 2022

Prader-Willi Syndrome (PWS) – Pipeline by OT4B, 2022

Prader-Willi Syndrome (PWS) – Pipeline by Saniona AB, 2022

Prader-Willi Syndrome (PWS) – Pipeline by Soleno Therapeutics Inc, 2022

Prader-Willi Syndrome (PWS) – Pipeline by Taysha Gene Therapies Inc, 2022

Prader-Willi Syndrome (PWS) – Pipeline by Tonix Pharmaceuticals Holding Corp, 2022

Prader-Willi Syndrome (PWS) – Dormant Projects, 2022

Prader-Willi Syndrome (PWS) – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Prader-Willi Syndrome (PWS), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently asked questions

Prader-Willi Syndrome (PWS) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Prader-Willi Syndrome (PWS) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Prader-Willi Syndrome (PWS) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.